Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
$81.63
$0.00
$35.11
$82.74
N/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
$1.00
+0.5%
$0.85
$0.64
$2.01
$40.14M-0.7836,784 shs4,643 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$112.46
+1.8%
$105.36
$62.69
$119.96
$139.89B0.267.75 million shs5.26 million shs
Bio-Techne Co. stock logo
TECH
Bio-Techne
$48.69
+0.8%
$50.02
$46.01
$83.62
$7.63B1.461.37 million shs1.19 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
0.00%0.00%0.00%0.00%0.00%
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-1.98%-10.00%-1.00%+0.50%-49.62%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+1.32%-0.59%+12.81%-5.92%+72.92%
Bio-Techne Co. stock logo
TECH
Bio-Techne
-3.09%-0.04%+1.24%-24.95%-39.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/AN/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
2.7324 of 5 stars
3.55.00.00.00.60.81.3
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.7217 of 5 stars
2.43.04.24.12.82.51.9
Bio-Techne Co. stock logo
TECH
Bio-Techne
4.9224 of 5 stars
4.23.01.74.23.81.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
0.00
N/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
3.00
Buy$5.17419.26% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.78
Moderate Buy$110.55-1.70% Downside
Bio-Techne Co. stock logo
TECH
Bio-Techne
2.45
Hold$72.0047.87% Upside

Current Analyst Ratings Breakdown

Latest GILD, AAAP, TECH, and BRNS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/30/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$59.00
5/21/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/9/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $70.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$72.00 ➝ $63.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$75.00 ➝ $60.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $75.00
4/25/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$130.00 ➝ $135.00
4/25/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$132.00 ➝ $125.00
4/25/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/22/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$125.00
(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
$14.97M2.68N/AN/A$4.85 per share0.21
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.74B4.87$8.88 per share12.66$15.44 per share7.28
Bio-Techne Co. stock logo
TECH
Bio-Techne
$1.21B6.31$1.72 per share28.30$13.15 per share3.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/A0.00N/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-$73.35M-$1.64N/AN/AN/AN/A-34.26%-29.30%8/14/2025 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$4.75303.9513.870.711.67%31.63%10.38%8/14/2025 (Estimated)
Bio-Techne Co. stock logo
TECH
Bio-Techne
$168.10M$0.8249.1824.722.8813.22%12.73%9.75%8/6/2025 (Estimated)

Latest GILD, AAAP, TECH, and BRNS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-$0.34-$0.49-$0.15-$0.49N/AN/A
5/7/2025Q3 2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
4/24/2025Q1 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.77$1.81+$0.04$1.04$6.77 billion$6.67 billion
3/20/2025Q4 2024
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-$0.50-$0.51-$0.01-$0.51N/A$14.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.81%+2.74%66.53%10 Years
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.320.66%N/A39.02%N/A

Latest GILD, AAAP, TECH, and BRNS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.793%6/13/20256/13/20256/27/2025
5/19/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
N/A
8.93
8.93
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.24
1.50
1.20
Bio-Techne Co. stock logo
TECH
Bio-Techne
0.14
3.94
2.77

Institutional Ownership

CompanyInstitutional Ownership
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
25.20%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Bio-Techne Co. stock logo
TECH
Bio-Techne
98.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Advanced Accelerator Applications stock logo
AAAP
Advanced Accelerator Applications
N/AN/AN/ANot Optionable
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
10740.34 million37.01 millionN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Bio-Techne Co. stock logo
TECH
Bio-Techne
3,000156.77 million151.92 millionOptionable

Recent News About These Companies

Bio-Techne (NASDAQ:TECH) Upgraded at Wall Street Zen
Bio-Techne Corporation (TECH): A Bull Case Theory
Bio-Techne to Present at Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Advanced Accelerator Applications stock logo

Advanced Accelerator Applications NASDAQ:AAAP

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.

Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$1.00 +0.01 (+0.51%)
Closing price 03:50 PM Eastern
Extended Trading
$0.97 -0.03 (-2.91%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$112.46 +2.00 (+1.81%)
Closing price 04:00 PM Eastern
Extended Trading
$113.00 +0.54 (+0.48%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$48.69 +0.38 (+0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$48.80 +0.11 (+0.23%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.